NASDAQ:UTHR
United Therapeutics Corporation Stock News
$266.22
+5.71 (+2.19%)
At Close: May 07, 2024
United Therapeutics Corporation (UTHR) CEO Dr. Martine Rothblatt on Q2 2022 Results - Earnings Call Transcript
02:32pm, Wednesday, 03'rd Aug 2022
United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2022 Results Conference Call August 3, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Dr. Martine Rothblatt - Chairperson, CEO Michael
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
01:32pm, Wednesday, 03'rd Aug 2022
United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.
United Therapeutics (UTHR) Q2 Earnings Lag Estimates
08:17am, Wednesday, 03'rd Aug 2022
United Therapeutics (UTHR) delivered earnings and revenue surprises of -41.22% and 0.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
06:00am, Wednesday, 27'th Jul 2022
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
10:51am, Tuesday, 19'th Jul 2022
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Roaring Stocks to Hold for the Next 20 Years
11:00am, Saturday, 16'th Jul 2022
Their persistent bullishness -- especially in this rocky environment -- is a testament to their long-term potential.
7 Biotech Stocks With Key Catalysts Coming in July
06:15am, Monday, 27'th Jun 2022
Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inv
Buy These 3 Low-Beta Stocks to Sail Through a Choppy Market
10:09am, Friday, 24'th Jun 2022
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. United Therapeutics (UTHR), Sanderson (SAFM) and AMN Healthcare (AMN) are well poised to gain.
Best Momentum Stocks to Buy for June 21st
10:24am, Tuesday, 21'st Jun 2022
IMO, PAG and UTHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 21, 2022.
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
04:30pm, Friday, 03'rd Jun 2022
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
11:33am, Wednesday, 25'th May 2022
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
11:18am, Tuesday, 24'th May 2022
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
7 Biotech Stocks With Key Catalysts for May
06:35am, Wednesday, 11'th May 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on Investo
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
12:47pm, Thursday, 05'th May 2022
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2022 Results - Earnings Call Transcript
12:06pm, Wednesday, 04'th May 2022
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2022 Results Conference Call May 4, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson, CEO Michael Benkow